BioPharma Dive October 8, 2024
“The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
Since stepping down as CEO of Alnylam Pharmaceuticals three years ago, John Maraganore has lent his talents widely, joining the boards of up-and-coming biotechnology companies, advising them on strategy and allying with some of the venture firms that back those young drugmakers.
His latest role returns him to his Alnylam roots. On Tuesday, City Therapeutics launched with a plan to build the next generation of the “RNA interference” medicines Alnylam pioneered. Maraganore, who co-founded City with a group of venture capitalists, scientists and other Alnylam veterans, will serve as the biotech’s executive chair.
...Today's Sponsors
Today's Sponsor